Welcome to our dedicated page for Phibro Animal Health news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (PAHC) will participate in the Morgan Stanley Annual Global Healthcare Conference. President and CEO Daniel Bendheim, COO Larry Miller, and CFO Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at the New York Marriott Marquis in New York.
A live audio presentation will be accessible via the company’s Investor Relations website, with a replay archived on the company’s website after the event.
Phibro Animal Health (Nasdaq: PAHC) reported fourth quarter 2026 net sales of $396.7 million, up 5% year over year, with net income of $21.7 million, up 26%, and adjusted EBITDA of $64.2 million, up 29%. Adjusted diluted EPS rose 35% to $0.85. Gross margin for the quarter expanded 490 basis points to 33.9%, aided by favorable mix and a $4.3 million tariff recovery benefit.
For fiscal 2026, net sales increased 17% to $1,518.1 million and net income rose to $99.7 million, with adjusted EBITDA up 39% to $255.0 million and adjusted diluted EPS up 48% to $3.22. Phibro issued fiscal 2027 guidance for net sales of $1.55–$1.60 billion, adjusted EBITDA of $258–$268 million, and adjusted net income of $140–$147 million. The company plans to close its Chicago Heights manufacturing facility by summer 2027, affecting about 100 employees, and will shift production to other sites and contract manufacturers.
Phibro Animal Health (Nasdaq: PAHC) plans to release its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after market close. Management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time, accessible via the company’s investor website or designated phone lines.
Phibro Animal Health (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is payable on September 23, 2026 to shareholders of record as of September 2, 2026.
Phibro Animal Health (Nasdaq: PAHC) will participate in the Stifel Jaws & Paws Conference on May 27, 2026, at 9:45 AM ET in New York.
Senior executives will address analysts and investors, with a live audio webcast and replay available on the company’s investor relations website.
Phibro Animal Health (Nasdaq: PAHC) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 1:40 PM ET in Las Vegas. Executives Daniel Bendheim, Larry Miller and Glenn David will address analysts and investors. A live audio webcast and archived replay will be available on the company investor site.
Phibro Animal Health (Nasdaq: PAHC) reported Q3 FY2026 results: net sales $383.5M (+10%), net income $24.0M (+15%), adjusted EBITDA $60.8M (+11%) and adjusted diluted EPS $0.76 (+19%).
The company updated FY2026 guidance to $1.46B–$1.50B net sales and $247M–$255M adjusted EBITDA, and expanded its revolving credit facility by $125M.
Phibro Animal Health (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on June 24, 2026 to shareholders of record at the close of business on June 3, 2026.
Phibro Animal Health (Nasdaq: PAHC) launched a companywide Sustainable Solutions Platform (SSP) and introduced Verratain Verified Sustainability Solutions, a master brand of low‑carbon microalgae feed ingredients. The initial Verratain line, via a strategic partnership with VAXA Technologies, includes Verratain Spirulina and Verratain Omega Oil and targets Scope 3 emissions in feed supply chains. Phibro appointed Peter Bunce as Head of Sustainable Solutions and expects initial sales within the coming months.
Phibro Animal Health (Nasdaq: PAHC) will announce third-quarter results on Wednesday, May 6, 2026 after the market close.
Management will host a conference call and webcast on Thursday, May 7, 2026 at 9:00 AM ET. Live audio and presentation slides will be available at https://investors.pahc.com; replay posted about two hours after the event.